JNCCN 360

Advertisement

Advertisement

Ana Maria Arance Fernandez, MD, PhD, on Melanoma Treatment in Light of the IMspire170 Trial

Kathleen Colson, RN, BSN, BS, on Preventing Infusion Reactions to Daratumumab

Alexander N. Shoushtari, MD, on Dosing Nivolumab

Recent

SITC 2019: Atezolizumab Monotherapy Versus Chemotherapy in PD-L1–Selected Lung Cancer

SITC 2019: Adenovirus Plus Pembrolizumab in Resistant Melanoma

SITC 2019: Avelumab Plus FOLFOX and Cetuximab in Metastatic Colorectal Cancer

Prognostic Value of Residual Lymphadenopathy After Chemoimmunotherapy for CLL

Published

Medical Literature

KATE2 Trial: Updated Overall Survival With Immunotherapy Combination in Advanced Breast Cancer

Bevacizumab Plus Erlotinib or Erlotinib Alone in EGFR-Mutated Lung Cancer

Efficacy of Nivolumab in Patients With Advanced Ocular or Mucosal Melanoma

Nivolumab Plus Ipilimumab in Advanced Kidney Cancer: CheckMate 214 Update

Ongoing

Exploring the Evolving Role of PARP Inhibition and Immunotherapy in Gynecological Cancers

Changing Treatment Landscape of Metastatic Head and Neck Squamous Cell Carcinoma With Anti–PD-1/PD-L1 Agents

Combined CAR-T Targeting Yields High Response Rate in Myeloma

Tumor Mutational Burden, Neoantigens, and a Pathway to Predicting Response to Checkpoint Inhibitors

Available

Clinical Trials

Immunotherapy Clinical Trials at Fred Hutch Cancer Research Center

ClinicalTrials.gov Immunotherapy

Center for Immunotherapy Clinical Research Trials

Cancer Research Institute Immunotherapy Clinical Trials

NCCN Resources

Copyright © 2019 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.